Childhood leukaemia is a diagnosis that no family ever wants to endure.

While the treatment of most types of leukaemia has improved steadily over the years, a few specific types remain very difficult to treat.

One of these is called "mixed lineage leukaemia," and for children affected by this cancer, their chance of survival is only around 50 %.

A team of researchers led by Václav Veverka (IOCB Prague, Czech Republic), Zeger Debyser (KU Leuven, Belgium), and H. Courtney Hodges (Baylor College of Medicine, TX, USA) has recently uncovered a major new vulnerability of mixed lineage leukaemia.

Their findings, published in a recent issue of the journal PNAS, reports that a protein called LEDGF/p75 is regulated by phosphorylation, a molecular modification that changes the electrical charge of the LEDGF/p75 protein.

LEDGF/p75, or "lens epithelium-derived growth factor," is a protein that contributes to the regulation of gene expression.

It does so by tethering other proteins to a specific epigenetic mark on chromatin.

This chromatin tethering activity is hijacked in two important disease settings: HIV and mixed lineage leukaemia.

Unfortunately, until now little was known about the biological regulation of LEDGF/p75's interaction to binding partners, which limited the development of therapeutic targeting of LEDGF/p75 in human disease.

After an extensive structural analysis, the scientists uncovered molecular features crucial for interaction LEDGF/p75 with its binding partners.

To their surprise, they found out that this interaction is achieved through a structurally conserved binding mode common to all of the LEDGF/p75 binding partners.

This allowed them to identify previously unknown direct interactions between LEDGF/p75 and other major transcriptional regulatory factors.

These factors are well known in the world of gene regulation and include major regulators such as the Mediator complex.

Their findings demonstrate that LEDGF/p75 participates in a much larger network of factors involved in transcription elongation than what was previously recognized.

Importantly, they also revealed for the first time that binding between LEDGF/p75 and its interaction partners are strongly modulated by phosphorylation from an enzyme called casein kinase 2.

This major breakthrough allows researchers to target LEDGF/p75 interactions, which can be used to develop entirely new therapeutic strategies against mixed lineage leukaemia.

In an initial proof-of-concept demonstration, the team showed that elimination of phosphorylation sites in MLL1, one of the LEDGF/p75 interaction partners, reduces the ability of leukaemic cells to remain in a cancer-like state.

Interestingly, this interaction is only necessary for cancer and does not appear to be needed for normal function of blood cells.

In their studies, the researchers found that inhibiting the phosphorylation that permits LEDGF/p75 and MLL1 to bind provides a promising new therapeutic route against mixed lineage leukaemia.

Because this interaction is specific to cancer and is not necessary for normal function, additional studies in this area may help to provide more potent and less toxic cancer therapies.

"The power of structural biology is the ability to visualize the molecular interactions that contribute to human disease," Veverka says.

Based on their recent discovery, the researchers hope their findings will open new possibilities to improve the odds for the young patients affected by this aggressive leukaemia.

Source: IOCB Prague